Entinostat (MS-275)

Catalog No.S1053 Synonyms: SNDX-275

Entinostat (MS-275) Chemical Structure

Molecular Weight(MW): 376.41

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 150 In stock
USD 270 In stock
USD 770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 62 Publications

14 Customer Reviews

  • (A) U87 cells were cultured in the presence of DMSO, 1 uM MS-275 alone, 100 ng/ml IFN-λ1 alone, or both for the course of 4 d. Cell numbers were manually determined by hemacytometer counting at the indicated time points. (B, F) Cell proliferation of U87 cells or U87 spheroids in 3D culture with indicated treatment were performed using the WST-1 assay, which measures active cellular metabolism. (C) U87 spheroid formation in 3D culture was photographed at day 14 in culture (representative images are shown; 200x magnification). (D-E) Quantification of the relative sizes and numbers of U87 spheroids in (C). (G) Cell cycle analysis was performed in U87 cells with indicated treatment using propidium iodide staining. Numbers in the histogram show fractions (percent) of sub-G1, N, 2N, and polyploidy from left to right. (H) U87 cells with indicated treatment were stained with Annexin V-FITC and 7-AAD. Numbers indicate the percentage of FITC-positive cells (upper left quadrant). FITC, fluorescein isothiocyanate; 7-AAD, 7-Aminoactinomycin. In all panels, data represent the mean and SEM of at least three experiments.

    PLoS Biol 2014 12, e1001758. Entinostat (MS-275) purchased from Selleck.

    Inhibition of HDAC1-mediated DNMT1 deacetylation promotes DNMT1 proteasomal degradation. (A) Knockout of HAUSP potentiates HDAC inhibitor (HDACi)-induced DNMT1 degradation. Parental or HAUSP KO DLD1 cells were treated or not with 5 μM HDACi MS-275 for 72 hours and cell lysates were blotted with the indicated antibodies. (B) HDAC inhibition induces DNMT1 ubiquitination. HAUSP WT or KO cells were treated with or without HDACi for 24 hours and MG132 for 12 hours before being harvested to make cell lysates. DNMT1 immunoprecipitates were blotted with an antibody against ubiquitin. Because the abundance of DNMT1 in the HAUSP KO cells is lower than in WT cells, more KO cells were used than WT cells to obtain equal amounts of precipitated DNMT1 proteins. (C) DNMT1 is acetylated after HDACi treatment. DNMT1 immunoprecipitates from cells treated with HDACi were blotted with an antibody against acetylated lysine (Ac-K). (D) A DNMT1 acetylation site mutant is resistant to HDACi-induced degradation. HEK 293 cells were transfected with WT DNMT1 or a DNMT1 mutant lacking four known acetylation sites (K173R, K1113R, K115R, and K117R) and treated with MS-275 for 48 hours and with CHX for 24 hours. Cell lysates were blotted with the indicated antibodies. (E) Knockdown of HDAC1 decreases the abundance of DNMT1. RKO cells were treated with the indicated concentration of doxycycline (Dox) for 48 hours to induce expression of an shRNA directed against HDAC1. Western blots were performed with the indicated antibodies. (F) Knockdown of HDAC1 leads to increased acetylation of DNMT1. RKO cells expressing an inducible HDAC1 shRNA were treated with or without Dox (4 mg/ml) for 36 hours and then with MG132 for 12 hours. DNMT1 immunoprecipitates were blotted with an antibody against Ac-K. Cell lysates were also blotted with antibodies against HDAC1 and b-actin.

     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

  • The E3 ligase UHRF1 ubiquitinates DNMT1. (A) HDAC inhibition enhances DNMT1 interaction with UHRF1. HEK 293 cells were transfected with plasmids expressing Myc-DNMT1 and Flag-UHRF1 and treated with or without MS-275 for 24 hours. Myc-DNMT1 immunoprecipitates were blotted with the indicated antibodies. (B and C) HDAC inhibition enhances the interaction of endogenous DNMT1 and UHRF1. Cells were treated with or without MS-275 and UHRF1 (B) or DNMT1 (C) immunoprecipitates were blotted with the indicated antibodies. (D) UHRF1 ubiquitinates DNMT1. HEK 293 cells were transfected with the indicated plasmids. Antibodies against Myc immunoprecipitates were blotted with antibody against HA to detect ubiquitinated DNMT1. Myc-DNMT1D, DNMT1 mutant lacking the HAUSP-interacting domain. UHRF1DRING, UHRF1 with a RING domain deletion. (E) Knockdown of UHRF1 blocks HDACi-induced DNMT1 degradation. HEK 293 cells were transfected with control siRNA or siRNAs against UHRF1 and treated with or without MS-275. Western blotting was performed with the indicated antibodies. (F) Overexpression of UHRF1 leads to degradation of a DNMT1 mutant lacking the HAUSP-interacting domain (DNMT1D). Full-length DNMT1 or DNMT1D was cotransfected into HEK 293 cells with the indicated expression vectors. Cell lysates were blotted with the indicated antibodies. (G) DNMT1, HAUSP, UHRF1, HDAC1, and PCNA associate with Tip60. Flag-tagged Tip60 immunoprecipitates were blotted with the indicated antibodies.

     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

    HAUSP KO cells are more sensitive to HDACi-induced apoptosis.(A) HDAC inhibition induces apoptosis in HAUSP KO cells.HAUSP WT or KO cells were treated with or without MS-275 at the indicated concentration for 72 hours, then fixed and stained with propidium iodide. Flow cytometric analyses were used to profile sub-G1, G1, and G2-M cell populations. Apoptotic cells were quantified after the indicated clones were treated with either 5 or 10 μM MS-275. The means and SDs of three independent experiments were plotted (*P<0.001, t test). (B) HDAC inhibition induces apoptosis in HAUSP KO cells but leads to G2-M arrest in WT cells.Cell cycle profiles of HAUSP WT or KOcells that were treated or not with 5 μM MS-275. (C)HDAC inhibition increases the abundance of apoptotic cell markers. The indicated cells were treated with or without MS-275 for 72 hours.Cell lysates were blotted with antibodies against cleaved caspase 3 and β-actin. (D) Ectopic overexpression of DNMT1 in HAUSP KO cells suppresses apoptosis. HAUSP KO clones or HAUSP KO cells inducibly

    overexpressingDNMT1 were treatedwith 10 μM MS-275. Apoptotic cell populations were quantified by fluorescence-activated cell sorting (FACS) analyses (*P < 0.001, t test). Cell lysates from these cells were blotted with the indicated antibodies. (E) HDAC inhibition arrests the growth of HAUSP KO cells. DLD1, HAUSP KO, and KO cells ectopically expressing HAUSP were treated with the indicated concentration of MS-275 for 4 days. Cell numbers were determined and data from eight replicates were plotted (**P <0.001, t test). (FandG) HDACi inhibits tumor xenograft formation ofHAUSP KOcells.Athymic nudemice (five in each group)were injectedsubcutaneously and bilaterallywith cells of the indicated genotypes. Mice were treated with or without MS-275 at 15mg/kg for 4 weeks. Tumors were harvested and photographed (F). Tumor sizes of the indicated groupsweremeasuredweekly and theaveragevolumes at each timepoint were plotted (G).MANOVA analyses were performed to determine whether there was an overall difference of the tumor sizes, as well as whether there was a difference in development over time of tumor sizes between the two groups (P < 0.0001).
     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

  • Numerous APC (+) oligodendrocytes (middle upper panel) with ellipsoid nuclei labeled with Sytox (left upper panel) were observed in 8 week old Thy-1 mitoCFP control MONs. NF-200 (+) neurofilaments extended along the MON as linear individual fibers (right upper panel). A period of OGD (60 min) caused a significant loss of APC (+) oligodendrocytes, a gain in the appearance of pyknotic nuclei (dense, brighter nuclei, white arrows, OGD panel), and loss of NF-200 (+) axon structures, which were, replaced with axonal head and bulb formation (white asterisks). Pretreatment with SAHA (1uM) or MS-275 (1uM) effectively preserved APC (+) oligodendrocytes, together with numerous linear individual NF-200 (+) axons. Note fewer pyknotic nuclei (white arrows, SAHA and MS-275 panels) after OGD in MONs treated with SAHA or MS-275.

    J Neurosci 2011 31, 3990-9. Entinostat (MS-275) purchased from Selleck.

    Notch1ICD, Notch2ICD, and Notch3ICD were transduced into human aortic SMCs, which were then treated with HDAC inhibitors TSA or MS-275 or with vehicle DMSO (con). The top 2 rows are different exposures of the same blot to detect the epitope tags on the N ICD constructs. Longer (top row) and shorter ( second row) exposures are shown because t he level of N2ICD expression was lower than that of N1ICD and N3ICD. SMC markers were analyzed and were similarly induced by activation of each Notch r eceptor. Both TSA and MS-275 significantly suppressed the induction of SMC proteins by Notch activation.

    J Am Heart Assoc 2012 1, e000901. Entinostat (MS-275) purchased from Selleck.

  • LSD1 and HDAC inhibitors exhibit synergistic growth inhibition. Cells were simultaneously treated with pargyline or HDAC inhibitors for 48 h.

     

     

    Breast Cancer Res Treat 2012 131, 777-789. Entinostat (MS-275) purchased from Selleck.

    Histone acetylation in the spinal cord after HDACI treatment. Histone acetylation in the lumbar spinal cord of mice receiving i.t. SAHA (25 μg) or MS-275 (0.5 μg) for 30 min was analyzed by immunoblot (A, B) and immunofluorescent histochemistry (C) for antigens indicated. Animals receiving i.t. saline were used as control. Images of the H3K9/18ac signals in the left half of the lumbar spinal cord are shown in the first row in C. Immunosignals of indicated antigens in the superficial dorsal horn are presented in the rest rows in C.

    Mol Pain 2010 6, 51. Entinostat (MS-275) purchased from Selleck.

  • B. Confluent quiescent foreskin fibroblasts were treated with HDAC1 inhibitor or vehicle for 24 hours. Type I procollagen protein levels in whole cell lysates were determined by immunoblotting. A representative result of three independent experiments is shown. The band density was evaluated by densitometry. C. Under the same conditions, mRNA levels of the α1(I) collagen (COL1A1) gene were determined using reverse transcription quantitative real-time PCR. The graph represents -fold change in COL1A1 mRNA levels in comparison to unstimulated controls, which were arbitrarily set at 100. The mean and SD from three separate experiments are shown. * p<0.05 versus control cells treated with vehicle.

    PLoS One 2013 8, e74930. Entinostat (MS-275) purchased from Selleck.

    Inhibition of LSD1 activity by HDAC inhibitors. a MDA-MB-231 and MDA-MB-468 cells were exposed to indicated HDAC inhibitors for 24 h.

     

     

    Exp Dermatol 2010 19, 1096-1102. Entinostat (MS-275) purchased from Selleck.

  • HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h, and their expression of GRP78, PERK-eIF2α axis and ATF4, ATF3, CHOP and DR5 proteins.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Entinostat (MS-275) purchased from Selleck.

    HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h. ATF4, ATF3, CHOP and DR5 proteins were measured by Western blot.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Entinostat (MS-275) purchased from Selleck.

  •  

    HDAC inhibition increases SMN-luciferase reporter mRNA levels. qRT-PCR was used to measure increases of SMN-luciferase mRNA following treatment with HDAC inhibitors. Fold increase of mRNA was normalized to GAPDH.

    Biochem Bioph Res Co 2010 414, 25-30. Entinostat (MS-275) purchased from Selleck.

    Western blot analysis of Acetyl-H3 and H3. 0-20μM MS-275 was added.

     

     

    2011 Dr. Zhang of Tianjin Medical University. Entinostat (MS-275) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.
Targets
HDAC1 [2]
(Cell-free assay)
HDAC3 [2]
(Cell-free assay)
0.51 μM 1.7 μM
In vitro

MS-275 shows inhibitory to HDACs by 2'-amino group. MS-275 induces accumulation of p21WAF1/CIP1 and gelsolin in K562 cell. MS-275 could reduce S-phase cells and induce G1-phase cells in A2780 cell. MS-275 inhibits the proliferation of human tumor cell lines including A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 with IC50 from 41.5 nM to 4.71 μM, which due to HAD-inhibition. [1] MS-275 is not sensitive to other HDACs (4, 6, 8 and 10) with IC50 about/above 100 μM. [2] MS-275 shows great inhibition to human leukemia and lymphoma cells, including U937, HL-60, K562, and Jurkat. MS-275 also decreases expression of cyclin D1 and the antiapoptotic proteins Mcl-1 and XIAP. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SCC-3 NICzWVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\ueWREUUN3ME2wMlA3OSEQvF2= M{HYS3NCVkeHUh?=
ALL-PO NVzje3F5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjsTWM2OD1yLkC2N|U2KM7:TR?= NULiZYFYW0GQR1XS
697 M1HoTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlK2TWM2OD1yLkC5PVc3KM7:TR?= NIXQTG9USU6JRWK=
NCI-H748 NIjqTohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTBwMUCzN|Qh|ryP M2jIO3NCVkeHUh?=
NKM-1 NGHDZnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\VdW5KSzVyPUCuNVA6OTJizszN MlezV2FPT0WU
ES1 NV71XIlOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofyTWM2OD1yLkGxNlU2KM7:TR?= NWrqb4R{W0GQR1XS
NCI-H1963 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moj0TWM2OD1yLkGxOVc6KM7:TR?= MXnTRW5ITVJ?
NCI-H1417 MoX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTBwMUK5O|Qh|ryP M4rqOXNCVkeHUh?=
NEC8 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PkcWlEPTB;MD6xN|UzPyEQvF2= Mln5V2FPT0WU
CRO-AP2 M17kXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPWTWM2OD1yLkG2PFg6KM7:TR?= MXXTRW5ITVJ?
A3-KAW NY\qc4VzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rP[WlEPTB;MD6xO|YzPyEQvF2= Mnj1V2FPT0WU
SF539 Mn;jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn65TWM2OD1yLkG5OVk{KM7:TR?= MWLTRW5ITVJ?
NOS-1 Mm\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTBwMUm2NVkh|ryP NWLhZWVrW0GQR1XS
NTERA-S-cl-D1 M1y0fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIO4c2tKSzVyPUCuNlAyOTNizszN NGLpOI5USU6JRWK=
COR-L88 NUDzdm1jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;4TWM2OD1yLkKyPVU6KM7:TR?= NFTGUXpUSU6JRWK=
EM-2 NUTI[VQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nke2lEPTB;MD6yOFA4QSEQvF2= NFy3N3JUSU6JRWK=
KARPAS-45 NGe0cWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\idY9KSzVyPUCuNlc5OzNizszN NIXVfnRUSU6JRWK=
DSH1 M1jDNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvwTWM2OD1yLkK4O|A5KM7:TR?= M2jlR3NCVkeHUh?=
HT-144 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1v3OWlEPTB;MD6zNFI2PiEQvF2= NFHxUZBUSU6JRWK=
ATN-1 NYS2b2JIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTBwM{C1O|Yh|ryP MXLTRW5ITVJ?
HEL MojuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULpU3piUUN3ME2wMlMyOzR6IN88US=> NXLXc4U{W0GQR1XS
NB12 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjKT4s1UUN3ME2wMlMyPzV4IN88US=> NUfUcVRxW0GQR1XS
LU-139 Mmr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;GNIh7UUN3ME2wMlM{PTFizszN M{LRdnNCVkeHUh?=
J-RT3-T3-5 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVL6Uoc3UUN3ME2wMlM{PzF4IN88US=> NFTUU3NUSU6JRWK=
MOLT-13 MkDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTBwM{O4NUDPxE1? NFjKXHVUSU6JRWK=
SR MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTBwM{SyOlEh|ryP NWLpOWl2W0GQR1XS
CMK M{SxTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTBwM{W3Nlch|ryP M3XQXnNCVkeHUh?=
ES8 NHS2fHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTBwM{[wNlIh|ryP NGH5bYlUSU6JRWK=
LB647-SCLC NYr1S5YzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXyzbWRZUUN3ME2wMlM3PzNizszN NIfN[GtUSU6JRWK=
TE-8 MnLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTBwM{[5N|Uh|ryP M1zQSHNCVkeHUh?=
BV-173 Mn\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLNRWhoUUN3ME2wMlM4OTJzIN88US=> MWrTRW5ITVJ?
DEL M3TtZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTBwM{e0PFch|ryP NFHOOHVUSU6JRWK=
ARH-77 MkXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWr0blNqUUN3ME2wMlM5OTl|IN88US=> M1yxPHNCVkeHUh?=
NCCIT MmXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXL2[lhWUUN3ME2wMlM5PjR7IN88US=> NXPyfIZ3W0GQR1XS
RPMI-8402 NFrFUnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnL6TWM2OD1yLkO4O|AyKM7:TR?= Mn;4V2FPT0WU
MONO-MAC-6 NIjEOWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DEXmlEPTB;MD6zPFc4PiEQvF2= MV3TRW5ITVJ?
SK-MM-2 NWPXVXNUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUH3UnB6UUN3ME2wMlM6QDZ6IN88US=> NFTLWJFUSU6JRWK=
CHP-126 Mn;uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfLTWM2OD1yLkSwNlMyKM7:TR?= MlTEV2FPT0WU
A101D MljRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTBwNECzJO69VQ>? MnjBV2FPT0WU
SCH MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF25dVlKSzVyPUCuOFA{PDJizszN MXXTRW5ITVJ?
NMC-G1 M1HzO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LwUmlEPTB;MD60NFM3PyEQvF2= MX\TRW5ITVJ?
NCI-H209 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzUNoRkUUN3ME2wMlQxPjF|IN88US=> NXLlN25IW0GQR1XS
MOLT-16 M2r2VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXVb5RKSzVyPUCuOFExOTdizszN M1PZe3NCVkeHUh?=
RPMI-6666 MlLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{e1eGlEPTB;MD60NVEzKM7:TR?= M{C5VnNCVkeHUh?=
OPM-2 M1K5fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnPTWM2OD1yLkSxOVE{KM7:TR?= MULTRW5ITVJ?
MRK-nu-1 Mn;SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDqU3FuUUN3ME2wMlQ{OTV|IN88US=> NFTaTWhUSU6JRWK=
BC-1 MoDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnr0TWM2OD1yLkSzOFA{KM7:TR?= NUPybZRXW0GQR1XS
MHH-NB-11 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHmTWM2OD1yLkSzOFU{KM7:TR?= Mn3EV2FPT0WU
Ramos-2G6-4C10 Mm\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoflTWM2OD1yLkSzPFk4KM7:TR?= NXXpUZFbW0GQR1XS
LS-513 Mo\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HkWWlEPTB;MD60OFUxOSEQvF2= NGq4fIxUSU6JRWK=
K5 NXHJOZdrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTBwNEewNlUh|ryP MWPTRW5ITVJ?
HOP-62 MnPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIP6XlhKSzVyPUCuOFg{PThizszN MnLoV2FPT0WU
NCI-H187 NVLUN2NJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofKTWM2OD1yLkS5NlI4KM7:TR?= MkHuV2FPT0WU
BE-13 MkHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1:2[mlEPTB;MD60PVY3OSEQvF2= MkfkV2FPT0WU
HC-1 NWnhSGFST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fGTmlEPTB;MD61NFQ4OyEQvF2= MWTTRW5ITVJ?
ACN NHLtPY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrGTWM2OD1yLkWxNFI5KM7:TR?= MULTRW5ITVJ?
HCC1599 NWHaZ|JMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\DTZNKSzVyPUCuOVE2PyEQvF2= M2PtXXNCVkeHUh?=
MV-4-11 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPPVIpoUUN3ME2wMlU{ODRzIN88US=> MkjXV2FPT0WU
LC-2-ad MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4D3emlEPTB;MD61N|Y3OyEQvF2= MlrHV2FPT0WU
HL-60 NFv4Xo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEKxRpNKSzVyPUCuOVQzPjFizszN M{DDSHNCVkeHUh?=
NB17 NYLtTJE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTBwNUSzPEDPxE1? NGC1N2xUSU6JRWK=
TE-1 NIjiV49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDMTWM2OD1yLkW1N|A3KM7:TR?= NFvH[WRUSU6JRWK=
NCI-H524 NVvNXlVvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTBwNUW0NFEh|ryP NIPBRWxUSU6JRWK=
MZ7-mel NGqyUZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXPTWM2OD1yLkW2NVA2KM7:TR?= MVrTRW5ITVJ?
L-363 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LCWmlEPTB;MD61OlY2PyEQvF2= MXfTRW5ITVJ?
BL-41 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDqTXFtUUN3ME2wMlU3QDh7IN88US=> MV\TRW5ITVJ?
LU-134-A NVe2XpZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYe0dHc4UUN3ME2wMlU4ODd|IN88US=> NWXQcJZ7W0GQR1XS
SIG-M5 MlnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;6RYFEUUN3ME2wMlU4QDR6IN88US=> MUjTRW5ITVJ?
ONS-76 Mmm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7kTWM2OD1yLkW4NlQzKM7:TR?= NWSzSGliW0GQR1XS
KARPAS-299 NH3OZZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfyWnZKSzVyPUCuOVg2ODRizszN NEHHWoFUSU6JRWK=
DU-4475 Ml25S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTBwNUi3NFMh|ryP NGnSPI5USU6JRWK=
NB69 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TJb2lEPTB;MD61PVgzPSEQvF2= M324RXNCVkeHUh?=
MHH-PREB-1 NVnlc5k2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULzfWlzUUN3ME2wMlYxPzF7IN88US=> NFfMe4hUSU6JRWK=
LU-165 NIDUVHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTBwNkG4NVIh|ryP MmHSV2FPT0WU
LOUCY NYq5OpJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3RPHRYUUN3ME2wMlY{OzZ2IN88US=> Mki2V2FPT0WU
NCI-H526 M2HqOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7DTWM2OD1yLk[zOVQyKM7:TR?= NXy0cI5ZW0GQR1XS
KE-37 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXS4d2FKUUN3ME2wMlY1Ojd4IN88US=> MX;TRW5ITVJ?
NALM-6 Mke3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIflZ4ZKSzVyPUCuOlQ5PiEQvF2= NVf2UHM5W0GQR1XS
CW-2 NYT3R2ZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fYZWlEPTB;MD62OVc6PCEQvF2= MYnTRW5ITVJ?
SU-DHL-1 NWDSOZFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXWOmV7UUN3ME2wMlY2QTR5IN88US=> MnziV2FPT0WU
NB13 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PKOGlEPTB;MD62OlgyPyEQvF2= M1KxVXNCVkeHUh?=
QIMR-WIL NIjod4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjMTWM2OD1yLk[4N|Q{KM7:TR?= NHL5ZXhUSU6JRWK=
ECC12 M4HtbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDjVGVuUUN3ME2wMlcxODh4IN88US=> NHnab4FUSU6JRWK=
KALS-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLIO|lTUUN3ME2wMlcxPDl{IN88US=> NEnscZNUSU6JRWK=
COR-L279 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTBwN{C5PVYh|ryP MXTTRW5ITVJ?
NB14 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXzTWtKUUN3ME2wMlczPjF5IN88US=> MkXCV2FPT0WU
CCRF-CEM NFrNW25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTBwN{S2OlEh|ryP NGTFZY1USU6JRWK=
SW954 M4ixNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlWxTWM2OD1yLke1PVk6KM7:TR?= NX7Nem4{W0GQR1XS
IST-SL1 M3XncWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2X5N2lEPTB;MD63O|M1QCEQvF2= MkjSV2FPT0WU
LAMA-84 NHTGUmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PaU2lEPTB;MD63O|U3PyEQvF2= M2\rfHNCVkeHUh?=
Daudi Ml\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjhSoFKSzVyPUCuO|c3QDFizszN MYTTRW5ITVJ?
BC-3 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXNTWM2OD1yLke4N|A5KM7:TR?= NVPuSpFkW0GQR1XS
HCC2998 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYX0VXhGUUN3ME2wMlc5OzZizszN NHjEdnJUSU6JRWK=
NCI-H69 NIjONY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTGTWM2OD1yLkiwNVQ4KM7:TR?= MlHoV2FPT0WU
CPC-N M2HEUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTBwOEC1NlQh|ryP MoXYV2FPT0WU
NOMO-1 NWTPNFlTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnLbpRKSzVyPUCuPFExQDRizszN NY\PR5NLW0GQR1XS
CESS NH2yRo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTBwOEGxPVch|ryP NXLpXW9FW0GQR1XS
LC4-1 MmeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTBwOESwNFch|ryP MV\TRW5ITVJ?
BL-70 NHrPVFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4m0emlEPTB;MD64OVcxOiEQvF2= MXTTRW5ITVJ?
ES4 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXF[2dKSzVyPUCuPFU5PjhizszN NXLB[otwW0GQR1XS
HCE-T MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\zd2lEPTB;MD64O|E4OSEQvF2= MXLTRW5ITVJ?
JAR NGDTRWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnQNVZNUUN3ME2wMlg4QDJ5IN88US=> M1TQWnNCVkeHUh?=
ST486 M3r5Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTBwOEe5NVch|ryP NFS1SnRUSU6JRWK=
KS-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TNT2lEPTB;MD64PFA6PiEQvF2= NWfFdmJ7W0GQR1XS
GDM-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTBwOEi2PFch|ryP MkjqV2FPT0WU
EHEB M4rjWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUm1[3F1UUN3ME2wMlkzPTh3IN88US=> MmTmV2FPT0WU
LB2518-MEL MoHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXWyRnhDUUN3ME2wMlk{Ojh2IN88US=> MmPJV2FPT0WU
GOTO MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTBwOUWwO|Yh|ryP NHK0UFNUSU6JRWK=
LXF-289 MnP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzufGhHUUN3ME2wMlk2QTBzIN88US=> MUjTRW5ITVJ?
ES6 NED0VIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;qTWM2OD1yLkm2OFM4KM7:TR?= NXi2S3I1W0GQR1XS
OS-RC-2 NVu3b|dIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjU[XJKSzVyPUCuPVY5OyEQvF2= NF;YWnJUSU6JRWK=
DMS-153 NEOzNYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTBwOUe0Olkh|ryP M1zROnNCVkeHUh?=
SK-PN-DW Ml;BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPmTWM2OD1yLkm3PFMyKM7:TR?= NYrtVIdbW0GQR1XS
HH M4rE[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrM[WRKSzVyPUCuPVg6PTlizszN Mm\aV2FPT0WU
SH-4 Mo\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rtRWlEPTB;MT6wNlQyKM7:TR?= MmTBV2FPT0WU
MOLT-4 MonaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrwcWRKSzVyPUGuNFM1PTRizszN NEDPenpUSU6JRWK=
TGW M{W1OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUK4cYI5UUN3ME2xMlA4Pjd3IN88US=> M3;3e3NCVkeHUh?=
L-540 M4njc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\obop6UUN3ME2xMlExPjB2IN88US=> NF3yXIlUSU6JRWK=
PF-382 M4\DR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIf1SVBKSzVyPUGuNVE2OTNizszN MlPGV2FPT0WU
LC-1F M{i2Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfBfWJJUUN3ME2xMlEzODB5IN88US=> MlnLV2FPT0WU
OVCAR-4 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLIcGJKSzVyPUGuNVMyPjVizszN NWHCW2JjW0GQR1XS
A4-Fuk M4fKU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmS0TWM2OD1zLkG1N|Y1KM7:TR?= NF7O[3ZUSU6JRWK=
HCC2218 NWK5e4s3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDRdJRKSzVyPUGuNVY3PDFizszN MWfTRW5ITVJ?
HAL-01 NFHWVVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTFwMU[5OFMh|ryP Ml\sV2FPT0WU
IST-MEL1 MlKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjEO2ZKSzVyPUGuNVc3PTlizszN NVTDO|NDW0GQR1XS
NCI-H719 NGPNUJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jZcmlEPTB;MT6xO|g6QCEQvF2= MlSyV2FPT0WU
EVSA-T M2Sxemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2X0OGlEPTB;MT6xPFEyPCEQvF2= NGrJUJBUSU6JRWK=
SK-NEP-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;TTWM2OD1zLkKwNlY3KM7:TR?= Mn7YV2FPT0WU
OCUB-M MnLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;mTmlEPTB;MT6yNVQ5QSEQvF2= MoPCV2FPT0WU
MEG-01 NVfUNHNQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknBTWM2OD1zLkKyNVE5KM7:TR?= M17PVXNCVkeHUh?=
no-10 MlfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;RWWV4UUN3ME2xMlI{OTF{IN88US=> NVzITWpuW0GQR1XS
MHH-CALL-2 MnnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnhNJJKSzVyPUGuNlQ4OjFizszN MXrTRW5ITVJ?
SK-N-DZ MmLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTFwMkS3O|Yh|ryP MkfIV2FPT0WU
SCLC-21H MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUj5eI02UUN3ME2xMlI3PDd6IN88US=> MV;TRW5ITVJ?
CTV-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrFTWM2OD1zLkK3OFI2KM7:TR?= NHzxO4lUSU6JRWK=
NB1 NFzSbJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTuTWM2OD1zLkK3O|MzKM7:TR?= MVTTRW5ITVJ?
NCI-H64 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XpXmlEPTB;MT6yPFQ3OiEQvF2= M3LyPHNCVkeHUh?=
MDA-MB-134-VI MlvLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfQVYRKSzVyPUGuNlg2PzdizszN M1mybnNCVkeHUh?=
LB2241-RCC NG\2Z3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPlTWM2OD1zLkK4OlY{KM7:TR?= NWHueIdtW0GQR1XS
8-MG-BA NXzYTpFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTFwMki4OlYh|ryP NXjGSXJDW0GQR1XS
LP-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLkSXBsUUN3ME2xMlI6QTR5IN88US=> MmW1V2FPT0WU
LS-411N MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fyZWlEPTB;MT6zNFk6QCEQvF2= NH:4SJdUSU6JRWK=
CAL-148 NGHF[nRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3v3bmlEPTB;MT6zNlU1OiEQvF2= NFnG[IZUSU6JRWK=
NCI-H2171 M1LhTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHS3U21KSzVyPUGuN|Q2ODJizszN NXvOUYQ2W0GQR1XS
JiyoyeP-2003 NX7pSZRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfvd|RKSzVyPUGuN|U{QSEQvF2= MlzHV2FPT0WU
NCI-H2107 NWTmOnFIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofQTWM2OD1zLkO1PFg{KM7:TR?= M4DWZ3NCVkeHUh?=
BB30-HNC M2njT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nBWGlEPTB;MT6zPFk4QCEQvF2= NFjP[WFUSU6JRWK=
K-562 NXS1cmxyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TMRWlEPTB;MT6zPVIyQSEQvF2= MoXvV2FPT0WU
PSN1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFK3ZmJKSzVyPUGuOFIzQDdizszN NE\BN4NUSU6JRWK=
HCC2157 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTFwNEK2PVEh|ryP MnjXV2FPT0WU
SBC-1 NEX0Z3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTFwNEK3OFEh|ryP NGLvZoxUSU6JRWK=
MC116 NGr3SFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfCTWM2OD1zLkSzOlE2KM7:TR?= NVzTUZZSW0GQR1XS
KARPAS-422 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\EWGlEPTB;MT60OVM2QCEQvF2= M4myUXNCVkeHUh?=
LB996-RCC NX75V4c4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTFwNEexNFMh|ryP M3mxUnNCVkeHUh?=
MSTO-211H NEm3fZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjXWXN3UUN3ME2xMlQ4QTh5IN88US=> NI\jcIJUSU6JRWK=
BT-474 M4rHTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M365fGlEPTB;MT61NVc3PCEQvF2= NEDOfnFUSU6JRWK=
A388 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2r4SWlEPTB;MT61NVk1PSEQvF2= MVrTRW5ITVJ?
SJSA-1 NGDMfpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTFwNUKyOkDPxE1? M4P4VHNCVkeHUh?=
COLO-829 Mn:5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnnTWM2OD1zLkWzOVY1KM7:TR?= NIHDV3JUSU6JRWK=
KM-H2 M2HqN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PYcmlEPTB;MT61OlY4KM7:TR?= NHu3bVdUSU6JRWK=
GR-ST NF:4endIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2Dy[GlEPTB;MT61OlgzKM7:TR?= MXzTRW5ITVJ?
RPMI-8866 MnvtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnWTWM2OD1zLk[wNVQ1KM7:TR?= MVXTRW5ITVJ?
KG-1 M2DtSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vi[2lEPTB;MT62NVkxOSEQvF2= M3TsOnNCVkeHUh?=
NCI-H82 NVvQcld1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTFwNkO0NFYh|ryP NYHRPFNWW0GQR1XS
LB1047-RCC NXTHPYI2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\Nb3JKSzVyPUGuOlM1PTlizszN MmDVV2FPT0WU
KM12 MnjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTCV|hKSzVyPUGuOlQ4KM7:TR?= M3X1bHNCVkeHUh?=
NB5 NIHNW4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTFwNkW2O|ch|ryP M2XFZXNCVkeHUh?=
HDLM-2 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDJSoVKSzVyPUGuOlgzQDFizszN M3eyZXNCVkeHUh?=
KU812 NFP2U3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPD[mxKSzVyPUGuOlk3ODVizszN Mn\YV2FPT0WU
DB M2e2fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfEb|BKSzVyPUGuO|A{PTNizszN NYrneXdOW0GQR1XS
HD-MY-Z M2Tnemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWOxRphSUUN3ME2xMlc2OjN2IN88US=> M37LVXNCVkeHUh?=
KURAMOCHI M2m3Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HzRmlEPTB;MT63O|IxPyEQvF2= M2r6dHNCVkeHUh?=
ETK-1 M4DMZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILKO5pKSzVyPUGuO|g5PzlizszN MUnTRW5ITVJ?
SK-UT-1 M4DYPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTFwN{mzPFgh|ryP M3;se3NCVkeHUh?=
HUTU-80 MoW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoL6TWM2OD1zLke5OVA5KM7:TR?= NETreGpUSU6JRWK=
ES7 NWLhSVVMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TwOWlEPTB;MT64NFMxOiEQvF2= MkPyV2FPT0WU
SW872 NX;XUoRuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTFwOEGzPVUh|ryP MUXTRW5ITVJ?
TK10 NGDxSoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDFUY9LUUN3ME2xMlg{OTB6IN88US=> MnrWV2FPT0WU
LB831-BLC MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4i0S2lEPTB;MT64N|U3OyEQvF2= MlPlV2FPT0WU
TE-9 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPER25KSzVyPUGuPFQ1OjJizszN MVjTRW5ITVJ?
MLMA MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTFwOEiyN|Qh|ryP MV3TRW5ITVJ?
D-542MG MmX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDEVYdKSzVyPUGuPFk{PzNizszN NITadIxUSU6JRWK=
EW-16 NFi4b|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nOdGlEPTB;MT65NlczKM7:TR?= NF7heVBUSU6JRWK=
LOXIMVI NVXIe45bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXrTJNKSzVyPUGuPVMzQCEQvF2= MUXTRW5ITVJ?
GB-1 M4\LPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLHe2lKSzVyPUGuPVM5PjZizszN M4PQW3NCVkeHUh?=
IST-SL2 MlLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHYRng3UUN3ME2yMlAxOjZ{IN88US=> M1PwOXNCVkeHUh?=
LAN-6 NHHsXW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTJwMEG5OlYh|ryP Ml3xV2FPT0WU
NCI-H510A M4\ZWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIO0TYdKSzVyPUKuNFQ2ODJizszN M2TPVXNCVkeHUh?=
NCI-H1092 NXfy[YpyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXKTWM2OD1{LkC1NVI1KM7:TR?= NX3R[lhWW0GQR1XS
HT Moj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTJwMUC0OVQh|ryP Mn3nV2FPT0WU
RL95-2 NXLMfW1iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvkcoFKSzVyPUKuNVE1QDJizszN NXPTfFZvW0GQR1XS
NCI-H1355 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXm0WXM3UUN3ME2yMlEyPzl{IN88US=> M2fHVHNCVkeHUh?=
NCI-H720 MnPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fQemlEPTB;Mj6xOlg4OyEQvF2= MYDTRW5ITVJ?
NCI-H1522 M1TIVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH63cXdKSzVyPUKuNlE4OjNizszN M4S3dXNCVkeHUh?=
LB373-MEL-D Mk\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXhVpprUUN3ME2yMlI3QTB{IN88US=> NX7tT|VnW0GQR1XS
DG-75 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;OT2NKSzVyPUKuNlcyPDhizszN NFS2c2tUSU6JRWK=
ML-2 Ml3zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\XTWM2OD1{LkOyPFU2KM7:TR?= MkfEV2FPT0WU
SF126 NY[xeVJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmf5TWM2OD1{LkOzNFk1KM7:TR?= MUfTRW5ITVJ?
MPP-89 NGXRbGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTJwM{OxOFUh|ryP NFnpNZdUSU6JRWK=
NCI-H345 NGDEd2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PjXWlEPTB;Mj6zN|I4PyEQvF2= NXjKfmN2W0GQR1XS
LS-123 M{[2TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTJwM{S5N|Yh|ryP M2XLenNCVkeHUh?=
NB10 M{PLe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTJwNEGwPVIh|ryP NF3xR4xUSU6JRWK=
CGTH-W-1 MnS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rNNGlEPTB;Mj60NlI3PyEQvF2= Mlz3V2FPT0WU
CP66-MEL NFz4PZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjMfnlKSzVyPUKuOFc4PyEQvF2= NIH5bZhUSU6JRWK=
L-428 M3jRUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HuVmlEPTB;Mj60PFUzOSEQvF2= MlzBV2FPT0WU
DMS-79 MojUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTFS2hKSzVyPUKuOVQyODNizszN NXm0ZmlzW0GQR1XS
NCI-H1882 MmjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTJwNke1OlIh|ryP MX3TRW5ITVJ?
KGN MmTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGT0bmlKSzVyPUKuO|Y5PzZizszN NUfM[FNTW0GQR1XS
EW-1 NECxSIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojWTWM2OD1{Lke3NFg{KM7:TR?= MlnhV2FPT0WU
U-266 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTJwOES4NlMh|ryP MWXTRW5ITVJ?
COLO-320-HSR M17pXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPUR5g5UUN3ME2yMlg2PjRzIN88US=> MYXTRW5ITVJ?
KMOE-2 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTJwOEe3NVEh|ryP M3n2fnNCVkeHUh?=
BB49-HNC MoW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPhU4lKSzVyPUKuPVI1QCEQvF2= MUTTRW5ITVJ?
GI-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PiUGlEPTB;Mj65Nlk2PyEQvF2= NYnEZllMW0GQR1XS
NCI-H1304 M1j3dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTNwMEC1NVEh|ryP NXzwflNKW0GQR1XS
NCI-H2227 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTNwMEKwO|kh|ryP MlrGV2FPT0WU
U-87-MG M4[5Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3ET3lKSzVyPUOuNFM2OTNizszN MmDBV2FPT0WU
NCI-H747 M37iemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETyfWRKSzVyPUOuNFUzODZizszN NFXV[ppUSU6JRWK=
CTB-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXodZpKSzVyPUOuNFU{PzZizszN Moj3V2FPT0WU
RPMI-8226 NWPuTlM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{j3bGlEPTB;Mz6xOFM4QCEQvF2= MXLTRW5ITVJ?
NCI-H2141 NX73dmxuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTNwMU[1OlYh|ryP NVfXPJNEW0GQR1XS
IST-MES1 MkC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HUfmlEPTB;Mz6xPFI4QSEQvF2= NWHnXlluW0GQR1XS
TE-5 NEHaV2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTUTWM2OD1|LkKxN|QzKM7:TR?= NX3mUVNNW0GQR1XS
UACC-257 NUf5RmJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjZfVVKSzVyPUOuOFM3PTlizszN Mn7CV2FPT0WU
SK-N-FI M1z5eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3BTWM2OD1|LkS1NlI4KM7:TR?= NVzke3JVW0GQR1XS
MFH-ino MlPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LqSWlEPTB;Mz60OlU5QSEQvF2= MlHRV2FPT0WU
SF268 M4jzbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlG5TWM2OD1|LkS4NVc1KM7:TR?= Mm\mV2FPT0WU
TE-12 NYLt[JM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEK0RZRKSzVyPUOuOVE3QTlizszN NGrvfFNUSU6JRWK=
NB6 Mo\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTNwNUW1OlMh|ryP Mme4V2FPT0WU
DJM-1 MkLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTNwNUm4PVkh|ryP M{DpSnNCVkeHUh?=
MZ1-PC MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\RRmlEPTB;Mz62NVYzPCEQvF2= MYTTRW5ITVJ?
OCI-AML2 Moj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLPTWM2OD1|Lk[yOlcyKM7:TR?= M{TXNXNCVkeHUh?=
NCI-H1155 MnLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTNwN{C5OFch|ryP M4ThWXNCVkeHUh?=
RKO MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofSTWM2OD1|Lke3NVg6KM7:TR?= NGrq[phUSU6JRWK=
ECC4 Mm\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYm3[lNUUUN3ME2zMlk4OTl3IN88US=> MUHTRW5ITVJ?
BB65-RCC Mn;zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfrRolKSzVyPUOuPVc2PDdizszN MnK1V2FPT0WU
EB-3 MkHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjWZWhMUUN3ME2zMlk6PjN|IN88US=> MnXzV2FPT0WU
SHP-77 M3TVeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHT[VBUUUN3ME20MlAxPTJ2IN88US=> NHr1bmhUSU6JRWK=
NCI-H2196 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofoTWM2OD12LkC1OlI2KM7:TR?= MoLxV2FPT0WU
GI-ME-N NFfiNGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmGyTWM2OD12LkC2N|k6KM7:TR?= NHWwcXlUSU6JRWK=
MN-60 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\OTWM2OD12LkGwPFch|ryP M{iyPXNCVkeHUh?=
NCI-H1694 MnTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULwfJdMUUN3ME20MlE{PDB3IN88US=> NIrlPZZUSU6JRWK=
LU-65 M3\vdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnVenhiUUN3ME20MlE2OzN{IN88US=> MkjXV2FPT0WU
NCI-H1436 NHGwdJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTRwMUizN|Mh|ryP M3zPOXNCVkeHUh?=
KINGS-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTRwM{G0N|Ih|ryP Mmj1V2FPT0WU
GT3TKB NIi5e3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTRwM{OyOlgh|ryP M3zPS3NCVkeHUh?=
Becker NH\HRWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnRTWM2OD12LkO3N|EzKM7:TR?= NWP3W4FGW0GQR1XS
HCC1187 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvNWpRzUUN3ME20Mlg6PjV5IN88US=> M1P0W3NCVkeHUh?=
D-502MG NFvz[npIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTVwMEC0NVYh|ryP NED2bIpUSU6JRWK=
VA-ES-BJ MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LvdWlEPTB;NT6xN|c4QCEQvF2= NYLoW5ozW0GQR1XS
NB7 Mnu4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTVwMUSxNVIh|ryP MXHTRW5ITVJ?
SW962 NHnybWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkmyTWM2OD13LkO4PFE1KM7:TR?= NEj1WndUSU6JRWK=
no-11 NIPDUY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrRRpN1UUN3ME21Mlc3OzR|IN88US=> MULTRW5ITVJ?
KNS-81-FD MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\IUWpKSzVyPUWuPVA3QTRizszN NH35O4dUSU6JRWK=
COLO-684 MoP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vp[GlEPTB;NT65PVQ6PCEQvF2= NYS5dFg3W0GQR1XS
D-263MG NVzpepdXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3PO2x[UUN3ME22MlA5QDl3IN88US=> M3zCRnNCVkeHUh?=
EW-24 NYrwboRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrqfFdKSzVyPU[uNlg2OSEQvF2= M2jFUHNCVkeHUh?=
TE-10 MoC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWGyNHNrUUN3ME22MlQzPjJ|IN88US=> NW\jZm1DW0GQR1XS
EKVX MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTZwNE[zNlEh|ryP M4DIRXNCVkeHUh?=
NCI-H1648 M13Pcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVGxeY17UUN3ME22MlY4PTV5IN88US=> NYj1VXJtW0GQR1XS
LB771-HNC NVq5eWRiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;z[WlEPTB;Nj65NlMxOSEQvF2= NFvwN2tUSU6JRWK=
SK-MEL-1 NUfzfmQxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRThwMUOxOlYh|ryP M{fGUXNCVkeHUh?=
COLO-668 M3iz[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEL5S|FKSzVyPUiuNlc4QDZizszN NYm4XYpWW0GQR1XS
EW-12 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2mydGlEPTB;OD60NFgxOyEQvF2= MlTHV2FPT0WU
A253 MoXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRThwOES2OlEh|ryP NX2wZ4FbW0GQR1XS
NCI-H2126 M4PHR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvGbXRjUUN3ME24Mlg6OzF7IN88US=> M2D4XnNCVkeHUh?=
Calu-6 M1TldGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFT4T4FKSzVyPUiuPVkxPDJizszN NVvhcWtWW0GQR1XS
NCI-H23 MnjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XWfWlEPTB;OT6xO|c1PiEQvF2= MkT1V2FPT0WU
WSU-NHL NH3lSHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXpZnhKSzVyPUmuO|c1PzhizszN NIHDRWpUSU6JRWK=
MMAC-SF MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTlwOUe5NFQh|ryP NXnlcXRDW0GQR1XS
SK-LMS-1 MnT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13qTmlEPTB;MUCuNlg{PCEQvF2= MUfTRW5ITVJ?
GCIY MkX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTFyLkW5NlQh|ryP NWnKVnR[W0GQR1XS
TE-15 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XO[GlEPTB;MUGuOlAxPCEQvF2= NFvoZVRUSU6JRWK=
EoL-1-cell NIHOS2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYH4dJdUUUN3ME2xNU44Pjh{IN88US=> MV7TRW5ITVJ?
NCI-H2081 NYPHPHRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\aXmlEPTB;MUGuO|c5PiEQvF2= MV\TRW5ITVJ?
EW-3 NEDINpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTF{LkK0OlMh|ryP NGHQfm1USU6JRWK=
CAS-1 MkPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13KOmlEPTB;MUKuN|Y{OSEQvF2= NW\SPZNDW0GQR1XS
C2BBe1 NIHtWY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrWVHZKSzVyPUGyMlYyOzFizszN NFv6blBUSU6JRWK=
D-247MG MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDZTWM2OD1zMj63PVUzKM7:TR?= MlnrV2FPT0WU
NCI-SNU-5 MofQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDHPGlFUUN3ME2xNk45ODF|IN88US=> M1PBXnNCVkeHUh?=
LS-1034 M1\VeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlm1TWM2OD1zND6zPVc2KM7:TR?= MnPsV2FPT0WU
EW-18 NH\GPZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPGTWM2OD1zND60OFgh|ryP M{nDSHNCVkeHUh?=
Raji NVrFRYJoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\aN4VUUUN3ME2xOE42ODR7IN88US=> MnnDV2FPT0WU
D-283MED NFnlbJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzpVJVKSzVyPUG0MlYzPzFizszN NVWy[mZ5W0GQR1XS
MZ2-MEL M3P6OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXZdJlKSzVyPUG0Mlk3QTZizszN NUS2VWU6W0GQR1XS
NCI-SNU-16 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfOR41KSzVyPUG1MlQ3OzNizszN M3zzSHNCVkeHUh?=
P30-OHK MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTNTWM2OD1zNz63PFMyKM7:TR?= MYHTRW5ITVJ?
RXF393 MkLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnwNXNiUUN3ME2xPU4xOTh4IN88US=> MWPTRW5ITVJ?
NCI-H1395 NUfXNlZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml[5TWM2OD1{MD62O|A{KM7:TR?= M3TMN3NCVkeHUh?=
U-698-M MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HkeGlEPTB;MkCuO|A4PSEQvF2= NF\YXmFUSU6JRWK=
NCI-SNU-1 MmroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHZTWM2OD1{MD63NlI{KM7:TR?= NWjxO|ZlW0GQR1XS
SW684 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HQVmlEPTB;MkGuNVcyPiEQvF2= NIPTVpNUSU6JRWK=
NCI-H716 MnfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjwN3BKSzVyPUKxMlMyPTRizszN MWnTRW5ITVJ?
JVM-2 MlHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTzTWM2OD1{MT60NVM{KM7:TR?= MX3TRW5ITVJ?
NCI-H1581 M3S4U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\DS|hTUUN3ME2yNk41OTR6IN88US=> Mmf3V2FPT0WU
CA46 NIXCXI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHiTWM2OD1|MT62PVM3KM7:TR?= M4WyS3NCVkeHUh?=
SNB75 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVi3THhbUUN3ME2zN{43PTB|IN88US=> M2PYW3NCVkeHUh?=
KNS-42 NIDVRWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLJOFJKSzVyPUO1Mlk3OjRizszN NVrQU29QW0GQR1XS
TUR NG\2dolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjwTWM2OD1|Nj6wOVIyKM7:TR?= NXTtTY1yW0GQR1XS
REH MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTN5LkiyNVEh|ryP MmrQV2FPT0WU
EW-22 MmTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MomzTWM2OD12Mj6yPFg2KM7:TR?= MofrV2FPT0WU
NCI-H446 MkDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn24TWM2OD12Mj63PFU{KM7:TR?= MYHTRW5ITVJ?
ES3 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnz2TWM2OD12Mz6xN|M6KM7:TR?= Ml7XV2FPT0WU
EW-11 NUPSe|NmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTR2LkiyNVgh|ryP NVPTO|lLW0GQR1XS
RH-1 NYjWSZVTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTR5LkW4NVIh|ryP NYnYV4h2W0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo MS-275 exhibits great antitumor activity against human tumor xenografts except HCT-15 at 49 mg/kg. [1] MS-275 demonstrates promising therapeutic potential in both solid and hematologic malignancies, as well as regulation of physiologic and aberrant gene expression. [4] MS-275, combination with IL-2, has great antitumor activity to renal cell carcinoma xenograft model, which due to decreased T regulatory cells and increased splenocytes. [5]

Protocol

Kinase Assay:

[6]

+ Expand

Standard HDAC Assays:

Rat liver enzyme is diluted 1:6 with HDAC buffer. Recombinant human HDACs are diluted 1:4 in HDAC buffer. For standard HDAC assays, 60 μL of HDAC buffer is mixed with 10 μL of diluted enzyme solution at 30 °C. The HDAC reaction is started by adding 30 μL substrate solution in HDAC buffer followed by 30 min of incubation at 30 °C. The reaction is stopped by adding 100 μL trypsin solutions (10 mg/ml trypsin in 50 mM Tris-HCl [pH 8.0], 100 mM NaCl, 2 μM TSA). After a 20 min incubation period at 30 °C, the release of AMC is monitored by measuring the fluorescence at 460 nm (λex = 390 nm). Fluorescence intensity is calibrated using free AMC. For standard time course experiments, 20 pmol of substrate is used in the initial 100 μL HDAC reaction. Km and Vmax values are determined by measuring the fluorescence AMC generated by enzymatic cleavage of 2–50 pmol of substrate. The experimental data are analyzed using a Hanes plot. The AMC signals are recorded against a blank with buffer and substrate but without the enzyme.
Cell Research:

[2]

+ Expand
  • Cell lines: A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 cells
  • Concentrations: ~ 10 μM
  • Incubation Time: 3 days
  • Method:

    Cancer cells (5 × 103) are seeded into each well of 96-well plates and cultured with graded concentrations of MS-275 for 3 days. The cells are stained with 0.1 mg/mL neutral red for 1 hour in a CO2-incubator, and, after aspiration of the medium, OD540 of the neutral red solubilized with 50 μL of ethanol and 150 μL of 0.1 M Na2HPO4 is measured. The IC50 value is determined by plotting growth inhibition of the cells against the logarithm of the drug concentration.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: A2780, HT-29, HTC-15, KB-3-1, 4-1St, St-4, Capan-1 and Calu-3 cells are injected subcutaneously into the flank of nude mice.
  • Formulation: Dissolved with 0.05 N HCl, 0.1% Tween 80
  • Dosages: 12.3, 24.5 and 49 mg/kg
  • Administration: Administered orally once daily 5 days per week for 4 weeks
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 75 mg/mL (199.25 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 376.41
Formula

C21H20N4O3

CAS No. 209783-80-2
Storage powder
in solvent
Synonyms SNDX-275

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03179930 Recruiting Lymphoma|Relapsed|Refractory Memorial Sloan Kettering Cancer Center|Merck Sharp & Dohme Corp.|Syndax Pharmaceuticals June 7 2017 Phase 2
NCT03250273 Recruiting Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreactic Cancer Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Syndax Pharmaceuticals|Bristol-Myers Squibb November 6 2017 Phase 2
NCT02453620 Recruiting Breast Adenocarcinoma|HER2/Neu Negative|Invasive Breast Carcinoma|Metastatic Malignant Solid Neoplasm|Stage III Breast Cancer AJCC v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7|Stage IV Breast Cancer AJCC v6 and v7|Unresectable Solid Neoplasm National Cancer Institute (NCI) November 6 2015 Phase 1
NCT03552380 Recruiting Renal Cell Carcinoma Roberto Pili|Bristol-Myers Squibb|Syndax Pharmaceuticals|Indiana University School of Medicine|Hoosier Cancer Research Network August 31 2018 Phase 2
NCT03473639 Recruiting Metastatic Breast Cancer|Breast Cancer University of Virginia|Syndax Pharmaceuticals September 30 2018 Phase 1
NCT02936752 Recruiting Blasts 21-30 Percent of Bone Marrow Nucleated Cells|Myelodysplastic Syndrome|Previously Treated Myelodysplastic Syndrome National Cancer Institute (NCI) April 3 2017 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to use Entinostat(Catalog No.S1053) for animal study. What is your recommendation for the solvent? What is the role of PEG 300 in this case? Can I use DMSO only and dilute it with PBS or HBSS?

  • Answer:

    2%DMSO/30%PEG/68%Water is recommended. PEG is an important polymer that helps with the solubility of hydrophobic drugs. If you use DMSO only and dilute it with PBS or HBSS, Entinostat will likely to precipitate out since it has very low solubility in water.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Entinostat (MS-275) | Entinostat (MS-275) supplier | purchase Entinostat (MS-275) | Entinostat (MS-275) cost | Entinostat (MS-275) manufacturer | order Entinostat (MS-275) | Entinostat (MS-275) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID